Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase 2a Evaluation of Psilocybin (TRP-8802) Administration in Concert With Psychotherapy to Decrease Hyperphagia in Patients With Overeating Disorders

To see complete record on, please visit this link

Id: NCT05035927

Organisation Name: TRYP Therapeutics

Overal Status: Not yet recruiting

Start Date: October 2021

Last Update: September 5, 2021

Lead Sponsor: TRYP Therapeutics

Brief Summary: This is a single-center phase 2a open-label study to assess the efficacy and safety of a dose of psilocybin in subjects with hyperphagia resulting in overeating during both dosing sessions. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 24 weeks following the second of 2 doses. The total participation in the study will be up to 7 months. The study will assess change from baseline in body mass index (BMI). Safety will be assessed during dosing sessions and over a 24 week follow-up period.

  • Hyperphagia

Total execution time in seconds: 0.1682550907135